title: Can bevacizumab be a new treatment approach in metastatic melanoma?
authors.forename: M A Nahit
authors.initials: MA
authors.lastname: Sendur
authors.forename: N Y
authors.initials: NY
authors.lastname: Ozdemir
authors.forename: S
authors.initials: S
authors.lastname: Aksoy
authors.forename: M B
authors.initials: MB
authors.lastname: Akinci
authors.forename: N
authors.initials: N
authors.lastname: Zengin
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D004311:Double-Blind Method; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab